On Wednesday, Baird made a slight adjustment to the price target for Danaher Corporation (NYSE:), bringing it down to $277 from the previous figure of $278. Despite the minor reduction, Baird continues to advocate a positive outlook for the company, maintaining an Outperform rating.
The adjustment followed Danaher’s third-quarter results, which surpassed expectations, primarily due to strong performance in the Biotechnology segment and an increase in Cepheid respiratory products. The company experienced a robust growth in bioproduction orders, which rose by approximately high-single digits on a quarter-over-quarter basis. Danaher’s management also indicated a return to normal purchasing behaviors among its larger customers.
While Danaher’s third-quarter success was notable, the company has decided to keep its 2024 core growth and margin guidance unchanged. This decision suggests a more conservative forecast for the fourth quarter. Additionally, Danaher refrained from providing detailed guidance for 2025, prompting Baird to acknowledge the need for clarity on initial 2025 guidance assumptions and the rate at which broader end-market conditions are improving. These conditions include factors such as the market in China, the instrumentation sector, and the emerging biotech industry.
Baird’s commentary highlighted that, although the immediate future poses certain uncertainties, their stance on Danaher’s medium-term prospects and portfolio composition remains positive. The firm’s analysts believe that the company is well-positioned for growth, even as questions linger regarding the initial guidance for 2025 and the overall pace of recovery in various end-markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
